STOCK TITAN

Shattuck Labs (STTK) grants 381,600-share option to CBO vesting through 2030

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported an equity award and a share disposition. On January 10, 2026, DeYoung was granted a stock option to purchase 381,600 shares of common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option vests on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to continued service. On the same date, 5,699 shares of common stock were disposed of at $4.75 per share, after which DeYoung directly owned 75,766 shares of common stock.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeYoung Casi

(Last) (First) (Middle)
C/O SHATTUCK LABS, INC.
500 W. 5TH STREET, SUITE 1200

(Street)
AUSTIN TX 78701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/10/2026 F 5,699 D $4.75 75,766 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock $4.75 01/10/2026 A 381,600 (1) 01/10/2036 Common Stock 381,600 $0 381,600 D
Explanation of Responses:
1. This option represents a right to purchase a total of 381,600 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer.
/s/ Andrew R. Neill, Attorney-in-fact for Casi DeYoung 01/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Shattuck Labs (STTK) report for Casi DeYoung?

Shattuck Labs reported that Chief Business Officer Casi DeYoung received a stock option for 381,600 shares of common stock and disposed of 5,699 shares of common stock on January 10, 2026.

What are the key terms of the 381,600-share stock option granted by Shattuck Labs (STTK)?

The option allows DeYoung to purchase 381,600 shares of Shattuck Labs common stock at an exercise price of $4.75 per share. One quarter vests on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to continued service.

How many Shattuck Labs (STTK) shares does Casi DeYoung own after the reported Form 4 transactions?

Following the reported transactions, Casi DeYoung directly owns 75,766 shares of Shattuck Labs common stock.

At what price were Shattuck Labs (STTK) shares disposed of in the Form 4 filing?

The Form 4 reports a disposition of 5,699 shares of Shattuck Labs common stock at a price of $4.75 per share on January 10, 2026.

Over what period will Casi DeYoung’s Shattuck Labs (STTK) stock option vest?

The 381,600-share option vests over approximately three years: one quarter on January 10, 2027, and the remaining three quarters in equal monthly installments through January 10, 2030, contingent on continued service.

What role does Casi DeYoung hold at Shattuck Labs (STTK) according to the Form 4?

Casi DeYoung is identified as an officer of Shattuck Labs, serving as the company’s Chief Business Officer.

Shattuck Labs, Inc.

NASDAQ:STTK

STTK Rankings

STTK Latest News

STTK Latest SEC Filings

STTK Stock Data

282.86M
49.78M
14.59%
72.19%
2%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN